Core Insights - Medtronic plc (NYSE:MDT) is recognized as one of the Top 15 Growth Stocks for Long-Term Investors [1] - The company is the largest producer of biomedical devices and implantable technologies globally, operating through four main segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes [2] Growth Strategy - Medtronic pursues growth through internal innovation and strategic acquisitions, with a strong focus on research and development (R&D) driving organic expansion [3] - The company has established a significant presence in emerging markets such as China, India, and Africa, which are characterized by large populations and rapidly expanding economies [3] Financial Performance - Revenue from emerging markets has been growing at a double-digit pace, outpacing growth in the United States, which contributes just over half of Medtronic's total revenue [4] - In fiscal Q2 2025, Medtronic recorded $4.2 billion in revenue from US operations and $4.3 billion from international markets [4] Acquisitions and R&D Investment - Since 2021, Medtronic has completed nine tuck-in acquisitions worth over $3.3 billion, reflecting its commitment to expanding capabilities and product offerings [5] - The company consistently spends over $2 billion annually on R&D, which is central to its continuous product innovation and leadership in the medical technology space [5] Dividend Performance - Medtronic has increased its dividend for 48 consecutive years, highlighting its financial stability and shareholder-focused approach [6] - The current quarterly dividend is $0.71 per share, with a dividend yield of 2.98% as of October 12 [6]